| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 890.53 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Background: Circulating endothelial cells (CEC) may be a biomarker of vascular injury and pro-thrombotic tendency, while
circulating endothelial progenitor cells (CEP) may be an indicator for angiogenesis and vascular remodelling. However, there
is not a universally accepted standardized protocol to identify and quantify these cells and its clinical relevancy remains to
be established.
Objectives: To quantify CEC and CEP in patients with venous thromboembolism (VTE) and with myeloproliferative
neoplasms (MPN), to characterize the CEC for the expression of activation (CD54, CD62E) and procoagulant (CD142) markers
and to investigate whether they correlate with other clinical and laboratory data.
Patients and Methods: Sixteen patients with VTE, 17 patients with MPN and 20 healthy individuals were studied. The CEC
and CEP were quantified and characterized in the blood using flow cytometry, and the demographic, clinical and laboratory
data were obtained from hospital records.
Results: We found the CEC counts were higher in both patient groups as compared to controls, whereas increased numbers
of CEP were found only in patients with MPN. In addition, all disease groups had higher numbers of CD62E+ CEC as
compared to controls, whereas only patients with VTE had increased numbers of CD142+ and CD54+ CEC. Moreover, the
numbers of total and CD62+ CEC correlated positively with the white blood cells (WBC) counts in both groups of patients,
while the numbers of CEP correlated positively with the WBC counts only in patients with MPN. In addition, in patients with
VTE a positive correlation was found between the numbers of CD54+ CEC and the antithrombin levels, as well as between
the CD142+ CEC counts and the number of thrombotic events.
Conclusions: Our study suggests that CEC counts may reveal endothelial injury in patients with VTE and MPN and that CEC
may express different activation-related phenotypes depending on the disease status.
Description
Keywords
Biomarkers Cell Count Endothelial Cells Humans Polycythemia Vera Risk Factors Stem Cells Thrombocythemia Essential Venous Thromboembolism